Przegla̜d Gastroenterologiczny最新文献

{"title":"The aftermath of COVID-19: Has the pandemic impaired the health-related quality of life of patients with aggressive inflammatory bowel disease?","authors":"Brigita Smolović, Miloš Lukić, Marina Jakšić, Stefan Bojović, Mirjana Nedović Vuković","doi":"10.5114/pg.2025.154646","DOIUrl":"10.5114/pg.2025.154646","url":null,"abstract":"<p><strong>Introduction: </strong>While the COVID-19 pandemic disrupted everyday life for all individuals, its impact was especially pronounced in patients with chronic illnesses. Among them, individuals undergoing biological therapy experienced additional difficulties related to continuity of care and access to medical professionals.</p><p><strong>Aim: </strong>We aimed to evaluate the health-related quality of life (HRQoL) in inflammatory bowel disease (IBD) patients, who were receiving biological therapy, before and during the COVID-19 pandemic.</p><p><strong>Material and methods: </strong>To our knowledge, this is the first study in the Balkans to examine the HRQoL exclusively in IBD patients treated with intravenous biological therapy, in the context of the COVID-19 epidemic. The cross-sectional study was conducted in two acts; in 2019 and during the second wave of the COVID-19 pandemic in 2020. All examinees filled out the short quality of life questionnaire. Patients were assessed for clinical disease activity using clinical activity indices. Also, they completed a questionnaire for the presence of depression - the Patient Health Questionnaire.</p><p><strong>Results: </strong>There were 90 patients in the group before the pandemic, and 94 IBD patients were examined during the pandemic. The proportion of patients with a poorer HRQoL increased during the pandemic (16.7% vs. 26.6%), but not statistically significantly (<i>p</i> = 0.103). The greatest impact on HRQoL in multivariate analysis both before and during the COVID-19 outbreak was shown by disease activity (<i>p</i> = 0.014; <i>p</i> = 0.023) and the presence of depressive symptoms (<i>p</i> = 0.001; <i>p</i> = 0.002). The percentage of employed IBD patients decreased significantly during the pandemic (from 64.4% before the pandemic to 47.9%; <i>p</i> = 0.024).</p><p><strong>Conclusions: </strong>An active disease and the presence of depressive symptoms had the greatest impact on impairment of the HRQoL of IBD patients, regardless of the pandemic. Mental health should be given more comprehensive attention in these patients.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"20 3","pages":"272-279"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12508380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structured exercise in patients with inflammatory bowel disease: a literature review.","authors":"Magdalena Achtenberg, Dorota Cibor, Małgorzata Zwolińska-Wcisło","doi":"10.5114/pg.2025.148473","DOIUrl":"10.5114/pg.2025.148473","url":null,"abstract":"<p><p>Many patients with inflammatory bowel disease (IBD) either do not respond or lose response to dedicated pharmacotherapy; therefore, physical exercise is gaining attention as a potential treatment adjunct. Recent research has highlighted the favorable relationship between physical activity and patient-reported outcomes. The reviewed studies suggest that structured exercise programs are safe and effective in the management of IBD. Yet the benefits of training trials need to be interpreted with caution due to the heterogeneity of the study methods and interventions, small sample sizes, and the absence of long-term follow-ups.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"20 1","pages":"36-40"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical diagnostic value of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for distinguishing functional heartburn from non-erosive reflux disease.","authors":"Lei Chen, Shaohua Luo, Jiaxi Chen, Zhenxing Li, Xiaorong Dai","doi":"10.5114/pg.2024.142910","DOIUrl":"10.5114/pg.2024.142910","url":null,"abstract":"<p><strong>Introduction: </strong>Functional heartburn (FH) and non-erosive reflux disease (NERD) are two prevalent diseases, with mean nocturnal baseline impedance (MNBI) and the post-reflux swallow-induced peristaltic wave (PSPW) index being used in their differentiation.</p><p><strong>Aim: </strong>We explored the clinical diagnostic value of MNBI and PSPW index on identifying FH and NERD.</p><p><strong>Material and methods: </strong>In total, 106 NERD and 82 FH patients were selected, and clinical data were collected. The mean low esophageal sphincter (LES) tone, distal contractile integral (DCI), contractile front velocity (CFV), and integrated relaxation pressure (IRP) were acquired. Acid exposure time (AET), total monitoring time, baseline impedance level, number of swallow-induced peristaltic wave reflux episodes within 30 s, total number of reflux episodes, and number of acid reflux episodes of NERD and FH patients were monitored, with AET, MNBI and the PSPW index being calculated. Correlations between MNBI and the PSPW index and pathological indicators of subjects, and the influence and diagnostic value of MNBI and the PSPW index for NERD and FH identification were analyzed.</p><p><strong>Results: </strong>The two groups differed significantly in AET, LES tone, total reflux episodes, acid reflux episodes and episodes of non-acid reflux. The NERD group displayed reduced MNBI and PSPW index levels. MNBI and the PSPW index were negatively associated with subject pathological indicators. MNBI, PSPW, LES tone, total reflux episodes and acid reflux episodes contributed to distinguishing NERD from FH. MNBI > 1975 and PSPW > 47.12 had high clinical application value for identifying NERD and FH.</p><p><strong>Conclusions: </strong>MNBI and PSPW, LES tone, total reflux episodes and acid reflux episodes aided in distinguishing NERD and FH. MNBI and PSPW combinative detection had high clinical application value for distinguishing NERD from FH.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"20 2","pages":"206-214"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease.","authors":"Anas Zaher, Hassan Elsaygh","doi":"10.5114/pg.2025.151891","DOIUrl":"10.5114/pg.2025.151891","url":null,"abstract":"<p><p>The global epidemic of obesity has led to a surge in metabolic-associated steatotic liver disease (MASLD), which poses a significant global health burden. Current therapeutic strategies primarily focus on lifestyle modifications, weight loss interventions, and the use of pharmacological agents such as glucagon-like peptide-1 receptor agonists (GLP-1RAs). Recently, the FDA approved resmetirom, a selective thyroid hormone receptor-β agonist. Both GLP-1RAs and resmetirom have individually demonstrated promising results in managing MASLD and associated metabolic disorders. However, the potential synergistic effects of combining these agents remain unexplored. This paper discusses the rationale for exploring the combination therapy of resmetirom and GLP-1RAs for managing MASLD.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"20 2","pages":"115-120"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose amoxicillin and pantoprazole regimen for <i>Helicobacter pylori</i> eradication: a multi-center, multinational randomized controlled trial.","authors":"Pezhman Alavinejad, Samira Mohamadi, Mohammad Javad Rezaei, Abazar Parsi, Ahmad Hormati, Eskandar Hajiani, Omid Eslami, Morteza Nayebi, Siamak Baghaei, Mohammed Hussien Ahmed, Quang Trung Tran, Azam Satari","doi":"10.5114/pg.2025.151887","DOIUrl":"10.5114/pg.2025.151887","url":null,"abstract":"<p><strong>Aim: </strong>The aim was to compare the efficacy of high-dose amoxicillin and pantoprazole dual therapy for <i>Helicobacter pylori</i> (HP) eradication in comparison with the clarithromycin-based quadruple regimen.</p><p><strong>Material and methods: </strong>The study was designed as a double blind, randomized controlled trial (RCT) on patients with confirmed HP infection referring to 8 medical centers in three countries - Iran, Egypt, and Vietnam - during October 2021 to March 2022. After obtaining written consent, the participants were randomly divided into two groups to receive either high-dose amoxicillin and pantoprazole dual therapy (group A) or the clarithromycin-based quadruple regimen (group B) for 2 weeks and followed by 4 weeks of therapy with pantoprazole. Then the rate of HP eradication in each group was determined and compared.</p><p><strong>Results: </strong>Finally, 619 patients with confirmed HP infection were included and randomly divided into two groups. Eradication rates in groups A and B were 68.3% and 85.6%, respectively, based on intention-to-treat (ITT) analysis, and 72.2% and 89.8% according to per-protocol (PP) analysis (<i>p</i> < 0.0001). Group A had a lower rate of adverse events than group B (22.0% vs. 40.1%, <i>p</i> < 0.0001). There was no significant difference in the complete compliance rate between groups A and B (90.7% vs. 89.0% respectively, <i>p</i> = 0.718).</p><p><strong>Conclusions: </strong>The results of the current study show that for treating HP infection, high-dose amoxicillin-PPI dual therapy failed to achieve high eradication rates compared with a clarithromycin-based quadruple regimen. Clarithromycin-based quadruple therapy for <i>H. pylori</i> eradication has a higher eradication rate despite more side effects, and similar compliance compared to high-dose dual therapy.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"20 2","pages":"178-184"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual dysfunction in patients with inflammatory bowel disease.","authors":"Magdalena Kaniewska, Konrad Lewandowski, Dorota Szydlarska, Grażyna Rydzewska","doi":"10.5114/pg.2025.151870","DOIUrl":"10.5114/pg.2025.151870","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel diseases (IBD) significantly influence sexual function due to their symptoms. The impact of the disease on sexuality and intimacy is a predominant concern for IBD patients, though data on sexual (SD) and erectile dysfunction (ED) and their determinants remain scarce.</p><p><strong>Aim: </strong>The aim of this study was to evaluate sexual function and identify predictors of SD among patients with IBD during biological treatment.</p><p><strong>Material and methods: </strong>This prospective study included 135 adult patients with Crohn's disease (<i>n</i> = 106) and ulcerative colitis (<i>n</i> = 29) who were selected for biological treatment based on established criteria (CD: CDAI > 300; UC: Total Mayo score > 6). Participants completed validated questionnaires on their sexual function: the Female Sexual Function Index (FSFI) and the International Index of Erectile Function-5 (IIEF-5), with a question from the Inflammatory Bowel Disease Questionnaire (IBDQ).</p><p><strong>Results: </strong>43.7% of patients reported SD, with similar proportions in men and women (<i>p</i> = 0.536). There was no significant correlation between the duration of IBD, type of medication or calprotectin levels and the results of the FSFI and IIEF-5 questionnaires. Self-reported limitations were greater for women compared to men (<i>p</i> < 0.001), with a significant correlation between them and both IIEF-5 and FSFI scores across both disease types (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>SD and ED among patients treated with biologics were associated with psychological factors but not disease severity. The type of medication used to treat the underlying disease did not influence the development of SD. These findings underscore the need for a comprehensive understanding of sexual health and psychological support for IBD patients.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"20 2","pages":"199-205"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S100B protein as a marker of minimal hepatic encephalopathy.","authors":"Wojciech Pisarek, Jakub Jarmołowicz, Elżbieta Poniewierka","doi":"10.5114/pg.2025.154659","DOIUrl":"10.5114/pg.2025.154659","url":null,"abstract":"<p><strong>Introduction: </strong>Minimal hepatic encephalopathy (MHE) is an overlooked impairment of central nervous system function in patients with acute and chronic liver diseases. Its impact on patients' quality of life, prognosis, and the incidence of overt hepatic encephalopathy has been proven. Due to diagnostic difficulties, searching for a serum biomarker for MHE appears to be extremely important.</p><p><strong>Aim: </strong>The aim of the study was to demonstrate a potential correlation between the serum levels of SB100P protein in patients with MHE symptoms and the levels of SB100P protein in patients with MHE.</p><p><strong>Material and methods: </strong>Given the association of hepatic encephalopathy with central nervous system damage, the study used the serum level of S100B protein in patients diagnosed with MHE based on the Psychometric Hepatic Encephalopathy Score (PHES) test.</p><p><strong>Results: </strong>The study results showed a statistically significant correlation between the serum S100B protein level and the PHES test result. It was also found that the S100B protein level was higher than the norm for the healthy population, as provided by the test manufacturer, in 83% of the patients.</p><p><strong>Conclusions: </strong>These results are promising, suggesting that further research is needed to verify the significance of S100B protein as a biomarker for MHE.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"20 3","pages":"325-329"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12508385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological rhythms of the gut and microbiota.","authors":"Albert Chodowiec, Mirosław Tarasewicz, Anna Łokić, Marcin Kazberuk, Anatol Panasiuk","doi":"10.5114/pg.2023.132437","DOIUrl":"https://doi.org/10.5114/pg.2023.132437","url":null,"abstract":"<p><p>Numerous physiological processes occurring in the digestive system are subject to circadian rhythms, which are regulated by the endogenous biological clock. The motor activity of the small intestine, large intestine, and rectum operates in a 24-hour system, with significant differences between day and night periods. It is primarily correlated with the time of meals, hormone secretion rhythms, and other activities undertaken by the organism. In recent years, numerous scientific reports have emerged about the fundamental role of circadian rhythms in the proper functioning of the gut microbiota. In addition, the microbiota and its metabolites also influence the host's daily cycles, which affects the overall state of their organism. The aim of this review is to outline the mechanisms of action and interactions between biological rhythms, gut motility, and the functioning of the gut microbiota.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"18-22"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of left ventricular assist devices on 30-day readmission and outcomes in non-variceal upper gastrointestinal bleeding: a nationwide analysis.","authors":"Umer Farooq, Zahid Ijaz Tarar, Adnan Malik, Muhammad Kashif Amin, Mustafa Gandhi, Moosa Tarar, Faisal Kamal","doi":"10.5114/pg.2023.134394","DOIUrl":"https://doi.org/10.5114/pg.2023.134394","url":null,"abstract":"<p><strong>Introduction: </strong>Bleeding, especially non-variceal upper gastrointestinal bleeding (NVUGIB), remains the most common cause of readmission in left ventricular assist device (LVAD) patients. Any readmission after NVUGIB carries a worse prognosis.</p><p><strong>Aim: </strong>To compare readmission outcomes in NVUGIB patients with and without LVAD.</p><p><strong>Material and methods: </strong>We identified adult NVUGIB patients using the National Readmission Database 2018 employing International Classification of Diseases, Tenth Revision (ICD-10) codes. The patients were grouped based on LVAD history. Proportions were compared using the Fisher exact test, and multivariate Cox proportional regression analysis was used to compute adjusted <i>p</i>-values. We used Stata version 14.2 to perform analyses considering 2-sided <i>p</i> < 0.05 as statistically significant.</p><p><strong>Results: </strong>The analysis included 322,342 NVUGIB patients, 1403 had a history of LVAD (mean age 64.25 years). The 30-day all-cause readmission rate in NVUGIB with LVAD was higher (24.31% vs. 13.92%, <i>p</i> < 0.001). Gastrointestinal bleeding as a readmission cause was more prevalent in the LVAD group. In patients with LVAD, NVUGIB readmissions required more complex endoscopic procedures, either requiring intervention during endoscopy or enteroscopy. There was no difference in mortality in NVUGIB readmissions (1.51% vs. 4.49%, <i>p</i> = 0.36); however, the length and cost of stay were higher in the LVAD group. Additionally, we identified novel independent predictors of readmission from NVUGIB in patients with LVADs.</p><p><strong>Conclusions: </strong>Readmissions in NVUGIB patients after LVAD require complex haemostatic intervention and are associated with greater resource utilization. To reduce readmissions and associated healthcare costs, it is essential to identify high-risk patients.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"175-185"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients - does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study.","authors":"Katarzyna Karłowicz, Konrad Lewandowski, Edyta Tulewicz-Marti, Katarzyna Maciejewska, Adam Tworek, Beata Stępień-Wrochna, Martyna Głuszek-Osuch, Michał Łodyga, Grażyna Rydzewska","doi":"10.5114/pg.2023.130126","DOIUrl":"10.5114/pg.2023.130126","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel disease (IBD) patients use a wide variety of immunosuppressive drugs, including biologics, but their effect on SARS-CoV-2 vaccine antibody levels remains a mystery.</p><p><strong>Aim: </strong>We analysed whether the drugs used in the treatment of IBD patients could affect the concentration of SARS-CoV-2 antibodies.</p><p><strong>Material and methods: </strong>This is a prospective, single-centre evaluation of the persistence of SARS-CoV-2 antibodies after vaccination at various time points: every 2 months throughout the 6^th month after the first dose.</p><p><strong>Results: </strong>We included a total of 346 vaccinated IBD patients in the study. A negative correlation between antibody level and time from full vaccination was confirmed for the following types of therapy: infliximab (rho = -0.32, <i>p</i> < 0.001), adalimumab (rho = -0.35, <i>p</i> = 0.025), and vedolizumab (rho = -0.50, <i>p</i> < 0.001). In the case of other, long-term drug administration, a negative correlation between antibody level and time from full vaccination was confirmed for mesalazine (rho = -0.35, <i>p</i> < 0.001), budesonide (rho = -0.58, <i>p</i> = 0.004), systemic glucocorticoids (rho = -0.58, <i>p</i> < 0.001), and azathioprine (rho = -0.44, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Due to the immunosuppressive and biological treatment, IBD patients are exposed to a shorter persistence of SARS-CoV-2 antibodies and require booster doses. The role of gastroenterologists in educating patients about the need to continue SARS-CoV-2 vaccination remains crucial.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"1 1","pages":"198-205"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70475487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}